

AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method for therapeutic treatment of a colon cancer which comprises administering an effective amount of compound represented by the general formula (I), or a pharmacologically acceptable salt thereof as an active ingredient:



<wherein

Z represents a sulfur atom;

R¹ represents substituted or unsubstituted phenyl;

R² represents

a hydrogen atom;

substituted or unsubstituted lower alkyl, or

$-C(=W^1)R^{12}$ { wherein W¹ represents an oxygen atom or a sulfur atom, and R¹²

represents a hydrogen atom; substituted or unsubstituted lower alkyl; substituted or

unsubstituted lower alkenyl; substituted or unsubstituted lower alkynyl; substituted or

unsubstituted cycloalkyl; substituted or unsubstituted aryl; a substituted or unsubstituted

heterocyclic group, $-Y^1R^{13}$ (wherein Y¹ represents an oxygen atom or a sulfur atom, and

~~R¹³ represents substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group), or -NR¹⁴R¹⁵ (wherein R¹⁴ and R¹⁵ are the same or different, and represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group, or R¹⁴ and R¹⁵ are combined together with the adjacent nitrogen atom to form a substituted or unsubstituted heterocyclic group))];~~

R³ represents substituted or unsubstituted lower alkyl; and

R⁴ represents substituted or unsubstituted phenyl>.

2.- 11. (Cancelled)

12. (Currently Amended) The method according to claim 1, 9, wherein R¹² is unsubstituted lower alkyl.

13. - 15. (Cancelled)

16. (Currently Amended) The method ~~An antitumor agent~~ according to claim 1, wherein R³ is substituted lower alkyl.

17. - 23. (Cancelled)

24. (Currently Amended) A compound represented by the formula (IA) or a pharmacologically acceptable salt thereof:



{wherein

Z has the same meaning as that mentioned above;

R¹ has the same meaning as that mentioned above;

R^{2A} represents -C(=W¹)R¹² (wherein W¹ and R¹² have the same meanings as those mentioned above, respectively);

R^{3A} represents

-(CH₂)_kNHSO₂R^{3B} [wherein k represents an integer of 1 to 6, and R^{3B} represents substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, or -NR^{7B}R^{8B} (wherein R^{7B} and R^{8B} are the same or different, and represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group, -OR⁹ (wherein R⁹ ~~represents~~ represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group), or -NR¹⁰R¹¹ (wherein R¹⁰ and R¹¹ are the same or different, and represent a

hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group, or R^{10} and R^{11} are combined together with the adjacent nitrogen atom to form a substituted or unsubstituted heterocyclic group), or R^7 and R^8 are combined together with the adjacent nitrogen atom to form a substituted or unsubstituted heterocyclic group)], $-(CH_2)_kNR^{7C}R^{8C}$ (wherein k has the same meaning as that mentioned above, and R^{7C} and R^{8C} have the same meanings as those of the aforementioned R^{7B} and R^{8B} , respectively), or $-(CH_2)_kNHC(=O)R^{7D}$ (wherein k has the same meaning as that mentioned above, and R^{7D} has the same meaning as that of the aforementioned R^{7B}); and R^{4A} has the same meaning as that of the aforementioned R^4).

25.- 34. (Cancelled)

35. (Currently Amended) The compound or a pharmacologically acceptable salt thereof according to claim 24 34, wherein R^{12} is unsubstituted lower alkyl.

36.- 37. (Cancelled)

38. (Withdrawn) The compound or a pharmacologically acceptable salt thereof according to claim 24, wherein R^{3A} is $-(CH_2)_kNHSO_2R^{3B}$ (wherein k and R^{3B} have the same meanings as those mentioned above, respectively).

39. - 41. (Cancelled)

42. (Currently Amended) The compound or a pharmacologically acceptable salt thereof according to claim 24, wherein R^{4A} is unsubstituted phenyl.

43. (Previously Presented) A medicament comprising the compound or a pharmacologically acceptable salt thereof according to claim 24 as an active ingredient.

44. - 47. (Cancelled)

48. (Previously Presented) A method for inhibiting a mitotic kinesin Eg5 which comprises administering an effective amount of the compound or a pharmacologically acceptable salt thereof according to claim 1.

49. - 50. (Cancelled)

51. (Previously Presented) A method for inhibiting a mitotic kinesin Eg5 which comprises administering an effective amount of the compound or a pharmacologically acceptable salt thereof according to claim 24.

52. (Cancelled)

53. (Previously Presented) A method for therapeutic treatment of a colon cancer which comprises administering an effective amount of the compound or a pharmacologically acceptable salt thereof according to claim 24.

54. - 56. (Cancelled)